If you have been reading about 药代动力学 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Higher temperatures accelerate germination, with 23 °C (73 °F) promoting faster colony formation than 19 °C (66 °F). Light exposure is unnecessary for early fungal growth—cultures in darkness develop healthier, more extensive mycelial networks. Developing mycobiont morphology provides insights into early symbiosis. In vitro, X. parietina forms septate, branched hyphae, which later develop into lobed structures, resembling early lichen thalli. Scanning electron microscopy reveals a dense, interwoven hyphal network, potentially facilitating photobiont interactions during natural lichenization. These adaptations support X. parietina's regenerative ability and symbiotic establishment across varied environments. Although X. parietina lacks specialized vegetative propagules, it has a regenerative capacity that enhances its ecological success. Older, apothecia-covered thalli detach along drought-induced cracks, while younger margins remain attached. When fragments land on suitable substrates, they regenerate new lobes along wound margins, acting as natural propagules. Field studies show a 150% laminal size increase in just 13 months in regenerating thalli. In a five-year experiment, X. parietina maintained 50% substrate coverage, despite losing 90% of its initial thallus area, as regrowth compensated for these losses. Total turnover (growth + loss) exceeded 170%, highlighting its dynamic life cycle.
First Minister of Wales Eluned Morgan offers Plaid Cymru an open invitation to support the Welsh Government's budget, scheduled to be delivered by Finance Secretary Mark Drakeford on 10 December. Wales's health secretary, Jeremy Miles announces that private healthcare will be used to help reduce the patient backlog in the NHS, with £50m allocated for health to be given to Wales's health boards to provide more appointments, tests and treatments. 20 November – Peter Kyle, the Secretary of State for Science, Innovation and Technology, tells the BBC that a ban on social media for under-16s in the UK is "on the cards". 21 November – Stephen Flynn, the SNP's leader at Westminster, says he will not seek a dual mandate by standing for the Scottish Parliament while he remains an MP. 22 November – Downing Street indicates that Israeli prime minister Benjamin Netanyahu would face arrest if he travelled to the UK following the issuing of an international arrest warrant for war crimes by the International Criminal Court. Former prime minister Gordon Brown publicly declares his opposition to a new law on assisted dying. 23 November – The UK government advertises for a new negotiator which it hopes will deliver a "reset" of the UK's relationship with the European Union. Secretary of State for Justice Shabana Mahmood writes to her constituents saying she is "profoundly concerned" about the Terminally Ill Adults (End of Life) Bill, not only for religious reasons but because of what it would mean for the state if one of its roles became helping people to die.
Alcohol dehydrogenase class-3 is an enzyme that in humans is encoded by the ADH5 gene. This gene encodes glutathione-dependent formaldehyde dehydrogenase or the class III alcohol dehydrogenase chi subunit, which is a member of the alcohol dehydrogenase family. Members of this family metabolize a wide variety of substrates, including ethanol, retinol, other aliphatic alcohols, hydroxysteroids, and lipid peroxidation products. Class III alcohol dehydrogenase is a homodimer composed of 2 chi subunits. It has virtually no activity for ethanol oxidation, but exhibits high activity for oxidation of long-chain primary alcohols and for oxidation of S-hydroxymethyl-glutathione, a spontaneous adduct between formaldehyde and glutathione. This enzyme is an important component of cellular metabolism for the elimination of formaldehyde, a potent irritant and sensitizing agent that causes lacrymation, rhinitis, pharyngitis, and contact dermatitis.
Sources: en.wikipedia.org
The main use for 4-aminosalicylic acid is for the treatment of tuberculosis infections. In the United States, 4-aminosalicylic acid is indicated for the treatment of tuberculosis in combination with other active agents. In the European Union, it is used in combination with other medicines to treat adults and children from 28 days of age who have multi-drug resistant tuberculosis when combinations without this medicine cannot be used, either because the disease is resistant to them or because of their side effects.
== Bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties" (PDF). Chinese Physics C. 41 (3) 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Silva, Robert J. (2011). "Chapter 13. Fermium, Mendelevium, Nobelium, and Lawrencium". In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements. Netherlands: Springer. pp. 1621–1651. doi:10.1007/978-94-007-0211-0_13. ISBN 978-94-007-0210-3. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.
Hazard research is published: the annual Global Carbon Budget study finds fossil CO2 emissions are still rising when if they stayed the same, the 50% likelihood to limit global warming to 1.5 °C would be exceeded around 2031 (5 Dec), the genetic testing company 23andMe confirms that the genetic privacy of around 7 million customers has been violated in the 23andMe data leak (5 Dec), a study using plasma proteomics aging clocks suggests nearly 20% of the population may show strongly accelerated age in one of 11 major organs, which it links to higher mortality risk (6 Dec), cumulative loneliness in mid-to-later life, a growing public health concern, is confirmed as potential substantial excess mortality risk factor with U.S. data (11 Dec), news outlets report on a study (13 Oct) finding ~82% of fish samples from two Michigan watersheds exceed daily consumption limit for adults of total PFOS (12 Dec), a study robustifies the link between women's preconception exposure to phthalates and lower fecundability, changes in reproductive hormones, and increased inflammation using EAGeR trial data (13 Dec), a study of meal timing using French NutriNet-Santé data indicates longer nighttime fasting periods may be superior to breakfast skipping in intermittent fasting (14 Dec), one of the first horizon scan risk screening studies by region on invasive species threats identifies 40 high-risk potential invaders to Florida (14 Dec).
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。